GlaxoSmithKline Consumer Healthcare has reached an agreement with Laclede, a privately held company, to purchase the dry mouth brand Biotene for $170 million.
The transaction is subject to regulatory review by competition authorities in the US and Europe, and is expected to complete by early 2009.
John Clarke, president of GlaxoSmithKline consumer healthcare, said: “The acquisition of Biotene extends our portfolio in therapeutic oral healthcare to include a proven treatment for dry mouth.
“This opportunity leverages our global capability with dental and medical professionals and is a further step towards our goal in GlaxoSmithKline of building and growing a diversified healthcare business.”
Comments